The confirmed drug-target interactions suggest an attenuation of pulmonary vascular remodeling (inhibition of PDE10A), modulation of Hepatitis C (HCV) viral response (inhibition of PKN2), and hypomagnesemia (inhibition of TRPM6). Therefore, we did not tofacitinib were confirmed as "promiscuous drugs", since they bind to proteins from families other than the primary therapeutic target.( ) Thus, both drugs may be potential candidates for adverse drug effects and further repurposing.